Zota Health Care Reports Strong Q1FY27 Results; Davaindia Network Expands Significantly

Zota Health Care Reports Strong Q1FY27 Results; Davaindia Network Expands Significantly​

Surat: Zota Health Care Limited, a leading pharmaceutical company dedicated to providing affordable, high-quality generic and proprietary medicines, announced its unaudited financial results for the first quarter of fiscal year 2027 (Q1FY27), which ended on June 30, 2026. The results highlighted substantial revenue growth driven by network expansion and robust market demand.

Zota Health Care Limited recorded consolidated revenues of ₹17,360.23 lakhs for Q1FY27. This figure represents a year-on-year (YoY) growth of 67.59%. The company’s operations are spread across marketing, export, and the retail pharmacy chain.

Q1FY27 Consolidated Financial Snapshot​

The company maintained strong operational performance, as reflected in its consolidated financial metrics for Q1FY27:


Details of sales across various segments during Q1FY27 are provided below:

Operational Metrics and Network Growth​

The company significantly expanded its retail presence during the quarter. Davaindia’s nationwide network reached 2,825 stores as of June 30, 2026. The Q1FY27 operational metrics highlight strong performance in store footprint expansion and customer engagement:


The company added 264 new stores during Q1FY27, including 201 COCO and 63 FOFO locations. Conversely, it closed 18 stores in the quarter, comprising 2 COCO and 16 FOFO units.

Strategic Investments and Key Appointments​

Zota Health Care Limited strengthened its healthcare ecosystem through several strategic investments and partnerships during Q1FY27. The company:

• Acquired an 80% stake in Globotask IT Consultancy Services Private Limited to support digital capabilities and technology infrastructure development.
• Reinforced commitment to scaling its retail platform by acquiring 39,794 equity shares of wholly owned subsidiary Davaindia Health Mart Limited through a rights issue.
• Made strategic investments in KMHP Ventures Limited and Curexis Ventures Private Limited to support the expansion of UGO Generic and SKIA retail formats.
• Enhanced its stake in Everyday Herbal Beauty Care Limited to support its backward integration strategy.

Furthermore, Mr. Akshay Kumar was appointed as the Brand Ambassador for Zota Health Care and UGO Generic, aimed at enhancing brand visibility nationwide.

Management Perspective​

Ketan Kumar Zota, Chairman of Zota Health Care Limited, commented on the performance, stating that the results provide a strong start to FY27, building upon successful execution in FY26. He noted that the momentum continued into Q1FY27 with the Davaindia network expanding to 2,825 stores, reinforcing acceptance of their affordable healthcare model.

Addressing the future outlook, Mr. Zota emphasized maintaining sustainable and disciplined growth moving forward. While acknowledging the significant long-term opportunity in generic medicines, he stated that the company plans to moderate the pace of expansion during Q2FY27. This measured approach will allow management to assess store-level performance and improve productivity before initiating the next phase of expansion.

ZOTA Stock Price Movement​

On Thursday, shares of Zota Health Care Limited edged higher, posting a gain of 0.83% to settle at ₹1260 after trading recovered ground in the market. The equity saw solid activity, with 145,417 shares changing hands during the session.